共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
3.
4.
Immunoablative therapy and hematopoietic stem cell transplantation (HSCT) is an intensive treatment modality aimed at 'resetting'
the dysregulated immune system of a patient with immunoablative therapy and allow outgrowth of a nonautogressive immune system
from reinfused hematopoietic stem cells, either from the patient (autologous HSCT) or a healthy donor (allogeneic HSCT). HSCT
has been shown to induce profound alterations of the immune system affecting B and T cells, monocytes, and natural killer
and dendritic cells, resulting in elimination of autoantibody-producing plasma cells and in induction of regulatory T cells.
Most of the available data have been collected through retrospective cohort analyses of autologous HSCT, case series, and
translational studies in patients with refractory autoimmune diseases. Long-term and marked improvements of disease activity
have been observed, notably in systemic sclerosis, systemic lupus erythematosus, and juvenile idiopathic arthritis, and treatment-related
morbidity and mortality have improved due to better patient selection and modifications of transplant regimens. Treatment-related
mortality has decreased to approximately 7%. Prospective, randomised, controlled clinical trials are ongoing or planned in
systemic sclerosis, systemic lupus erythematosus, and several nonrheumatological conditions. 相似文献
5.
Laurie C. Miller 《Biotherapy》1994,8(2):99-111
IL-1 and related cytokines have multiple biologic activities relevant to the rheumatic diseases. In addition to mediating inflammatory and immune responses, these proteins regulate many aspects of connective tissue metabolism. The cytokines interact in complex cascades: because of this, and various technical reasons, the exact role of cytokines in the pathogenesis of rheumatic diseases remains uncertain. However, considerable experimental data suggest that the abnormal regulation of cytokines contributes to such siseases as inflammatory arthritis, systemic lupus erythematosus, scleroderma, and dermatomyositis. Animal models of these diseases have contributed to understanding the role of cytokines in pathogenesis. Furthermore, drugs useful in treating these diseases affect cytokine pathways; some cytokines, their antagonists, or related substances have been used therapeutically to treat rheumatic diseases. The therapeutic use of these agents will likely increase as knowledge about the role of cytokines in the pathogenesis of rheumatic diseases expands.Abbreviations CSF
colony stimulating factor
- ELAM
endothelial leukocyte adherence molecule
- FGF
fibroblast growth factor
- ICAM
intercellular adhesion molecule
- IFN
interferon
- IL
interleukin
- LFA
lymphocyte function-associated antigen
- LIF
leukemia inhibitory factor
- MCAF
monocyte chemotactic/activitating factor
- MCP
monocyte chemoattractant protein
- MDP
muramyl dipeptide
- PAI
plasminogen activator inhibitor
- PBMC
peripheral blood mononuclear cells
- PDGF
platelet derived growth factor
- PG
prostaglandin
- PHA
phytohemagglutinin
- Ra
receptor antagonist
- SLE
systemic lupus erythematosus
- SSc
systemic sclerosis
- TGF
transforming growth factor
- TNF
tumor necrosis factor 相似文献
6.
Georg Schett 《Arthritis research & therapy》2009,11(1):210-6
This review summarizes the recent advances of osteoimmunology, a new research field that investigates the interaction of the
immune system with the skeleton. Osteoimmunology has contributed significantly to the understanding of joint destruction in
rheumatoid arthritis and other forms of arthropathies. In particular, the molecular regulation of osteoclast formation and
its control by proinflammatory cytokines have helped investigators to understand the mechanisms of bone erosion in rheumatic
diseases. Osteoimmunology has also allowed an improvement in our knowledge of the structure-sparing effects of antirheumatic
drug therapy. Moreover, recent advances in the understanding of the molecular regulation of osteophyte formation are based
on the characterization of the regulation of bone formation by inflammation. This review highlights the key insights into
the regulation of bone destruction and formation in arthritis. Moreover, concepts of how bone influences the immune system
are discussed. 相似文献
7.
8.
9.
Lipsky PE 《Arthritis research & therapy》2006,8(Z2):S4
IL-6 is a pleiotropic cytokine involved in both the initiation and the maintenance of the inflammatory and immunologic responses in certain autoimmune diseases. Blocking of these two complementary functions of IL-6 may confer additive, or even unique, benefits to the patient. The levels of both IL-6 and its soluble receptor (sIL-6Ralpha) are elevated to various degrees in many rheumatic diseases. IL-6 blockade has been shown to be beneficial both in experimental models and in human disease, and inhibition of IL-6 signaling with a molecule such as tocilizumab could prevent or reverse some of the complications typically associated with rheumatic diseases. 相似文献
10.
D Gloag 《BMJ (Clinical research ed.)》1985,290(6462):132-136
11.
12.
A D Broadhurst 《BMJ (Clinical research ed.)》1977,2(6084):456-457
13.
14.
Ceribelli A Yao B Dominguez-Gutierrez PR Nahid MA Satoh M Chan EK 《Arthritis research & therapy》2011,13(4):229
MicroRNAs (miRNAs) are endogenous, non-coding, single-stranded RNAs about 21 nucleotides in length. miRNAs have been shown
to regulate gene expression and thus influence a wide range of physiological and pathological processes. Moreover, they are
detected in a variety of sources, including tissues, serum, and other body fluids, such as saliva. The role of miRNAs is evident
in various malignant and nonmalignant diseases, and there is accumulating evidence also for an important role of miRNAs in
systemic rheumatic diseases. Abnormal expression of miRNAs has been reported in autoimmune diseases, mainly in systemic lupus
erythematosus and rheumatoid arthritis. miRNAs can be aberrantly expressed even in the different stages of disease progression,
allowing miRNAs to be important biomarkers, to help understand the pathogenesis of the disease, and to monitor disease activity
and effects of treatment. Different groups have demonstrated a link between miRNA expression and disease activity, as in the
case of renal flares in lupus patients. Moreover, miRNAs are emerging as potential targets for new therapeutic strategies
of autoimmune disorders. Taken together, recent data demonstrate that miRNAs can influence mechanisms involved in the pathogenesis,
relapse, and specific organ involvement of autoimmune diseases. The ultimate goal is the identification of a miRNA target
or targets that could be manipulated through specific therapies, aiming at activation or inhibition of specific miRNAs responsible
for the development of disease. 相似文献
15.
16.
17.
18.
Diseases such as degenerative or rheumatoid arthritis are accompanied by joint destruction. Clinically applied tissue engineering
technologies like autologous chondrocyte implantation, matrix-assisted chondrocyte implantation, or in situ recruitment of bone marrow mesenchymal stem cells target the treatment of traumatic defects or of early osteoarthritis. Inflammatory
conditions in the joint hamper the application of tissue engineering during chronic joint diseases. Here, most likely, cartilage
formation is impaired and engineered neocartilage will be degraded. Based on the observations that mesenchymal stem cells
(a) develop into joint tissues and (b) in vitro and in vivo show immunosuppressive and anti-inflammatory qualities indicating a transplant-protecting activity, these cells are prominent
candidates for future tissue engineering approaches for the treatment of rheumatic diseases. Tissue engineering also provides
highly organized three-dimensional in vitro culture models of human cells and their extracellular matrix for arthritis research. 相似文献
19.
20.
Inflammatory rheumatic diseases are generally multifaceted disorders and, therefore, measurement of multiple outcomes is relevant
to most of these diseases. Developments in outcome measures in the rheumatic diseases are promoted by the development of successful
treatments. Outcome measurement will increasingly deal with measurement of low levels of disease activity and avoidance of
disease consequences. It is an advantage for patient management and knowledge transfer if the same outcomes are used in practice
and in trials. Continuous measures of change are generally the most powerful and, therefore, are preferred as primary outcomes
in trials. For daily clinical practice, outcome measures should reflect the patients' state and have to be easily derivable.
The objective of this review is to describe recent developments in outcome measures for inflammatory rheumatic diseases for
trials and clinical practice, with an emphasis on rheumatoid arthritis. 相似文献